Metoprolol Succinate Extended Release and Ramipril Tablets | METAPROLATE R 50

Metoprolol Succinate Extended Release and Ramipril Tablets is a fixed-dose combination of two proven cardiovascular medicines — a beta-1 selective blocker and an ACE inhibitor — prescribed together to manage hypertension, chronic heart failure, and angina. Metoprolol Succinate controls heart rate and reduces cardiac workload through sustained release over 24 hours, while Ramipril relaxes blood vessels by inhibiting the ACE enzyme that narrows them. Together, they lower blood pressure more effectively than either drug alone and significantly reduce the long-term risk of heart attack, stroke, and kidney complications. This combination is taken once daily, with or without food, strictly as prescribed by a qualified physician.

What Are Metoprolol Succinate Extended Release and Ramipril Tablets?

Metoprolol Succinate Extended Release and Ramipril Tablets is a fixed-dose combination (FDC) cardiovascular medication that brings together two clinically established active pharmaceutical ingredients in a single oral tablet. Metoprolol Succinate is a beta-1 selective adrenoceptor blocking agent formulated in an extended-release delivery system that provides controlled, predictable drug release over a full 24-hour dosage interval. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the formation of angiotensin II — a hormone responsible for blood vessel constriction and elevated blood pressure. Together, these two molecules act through complementary mechanisms to reduce blood pressure, protect heart function, and lower the risk of serious cardiovascular events in adult patients.

How Do Metoprolol Succinate Extended Release and Ramipril Tablets Work?

Understanding the dual mechanism of this combination tablet helps explain why it is clinically superior to monotherapy for many patients.

Metoprolol Succinate — Beta-1 Selective Blockade

Metoprolol Succinate works by selectively blocking beta-1 adrenergic receptors located primarily in the heart. By blocking the action of catecholamines — particularly adrenaline — on these receptors, Metoprolol reduces the heart rate, decreases myocardial contractility, and lowers cardiac output. The extended-release formulation delivers the drug continuously over 24 hours through a multi-unit controlled-release pellet system, maintaining stable plasma concentrations and consistent beta-1 blockade throughout the day and night. This avoids the peak-and-trough fluctuations seen with immediate-release formulations and provides more uniform blood pressure control.

Ramipril — ACE Inhibition and Vasodilation

Ramipril works by inhibiting the angiotensin-converting enzyme (ACE), which is responsible for converting angiotensin I into angiotensin II — a potent vasoconstrictor that raises blood pressure and promotes sodium retention. By blocking this conversion, Ramipril causes vasodilation, reduces peripheral vascular resistance, lowers aldosterone secretion, and ultimately decreases blood pressure. It also reduces the workload on the heart and has been shown to offer protective effects on the kidneys in patients with hypertension and diabetes.

The Synergistic Effect

When combined, Metoprolol Succinate and Ramipril address blood pressure through two entirely different physiological pathways — cardiac output reduction and peripheral vasodilation. This dual action delivers more comprehensive and sustained blood pressure control than either agent achieves individually, making the combination particularly effective for patients with complex cardiovascular profiles.

Therapeutic Uses of Metoprolol Succinate Extended Release and Ramipril Tablets

This combination tablet is prescribed by doctors for the following clinically established indications:

• Hypertension (High Blood Pressure) — The primary indication for this combination. By simultaneously reducing heart rate and relaxing blood vessels, the tablet effectively lowers both systolic and diastolic blood pressure in adults with essential hypertension. Long-term control reduces the cumulative risk of stroke, heart attack, and end-organ damage.
• Chronic Heart Failure — Metoprolol Succinate has a well-established role in reducing mortality in patients with stable chronic heart failure. Combined with Ramipril, which reduces cardiac preload and afterload, this combination supports better cardiac output, reduces fluid retention, and improves overall heart function in heart failure patients.
• Angina Pectoris (Chest Pain) — Metoprolol Succinate reduces myocardial oxygen demand by lowering heart rate and contractility, which directly reduces the frequency and severity of angina episodes. The addition of Ramipril supports vascular health and reduces arterial stiffness, providing broader symptomatic relief.
• Post-Myocardial Infarction (Post-Heart Attack) — Both Metoprolol and Ramipril have independent evidence supporting their use after a heart attack to reduce the risk of a second cardiac event and improve long-term survival outcomes.
• Diabetic Nephropathy Prevention — Ramipril's protective effect on renal function makes this combination beneficial for hypertensive patients with diabetes who are at risk of kidney damage from chronic high blood pressure.

Dosage and Administration

Metoprolol Succinate Extended Release and Ramipril Tablets are intended for once-daily oral administration. The tablet must be swallowed whole with an adequate amount of liquid — approximately half a glass of water. It must not be chewed, crushed, or broken, as this would compromise the extended-release mechanism and alter drug delivery.

The usual starting dose is one tablet of the lower strength formulation (Metoprolol Succinate 25mg + Ramipril 2.5mg) once daily. If blood pressure remains inadequately controlled after 2–3 weeks of therapy, the treating physician may titrate the dose upward. The maximum approved adult daily dose is Metoprolol Succinate 100mg combined with Ramipril 10mg.

This combination tablet can be taken with or without food, as food does not significantly affect the absorption of either active ingredient. It is recommended to take it at the same time each day to maintain consistent plasma levels.

Dose adjustment is required in patients with hepatic impairment, renal impairment, or in elderly patients, where the lowest effective dose is always recommended. This fixed-dose combination is not suitable as initial therapy in patients whose Ramipril requirement begins at 1.25mg, as the minimum Ramipril dose in this combination is 2.5mg.

Common Side Effects of Metoprolol and Ramipril Tablets

Like all prescription medications, Metoprolol Succinate Extended Release and Ramipril Tablets may cause side effects in some patients. Most are mild, temporary, and resolve as the body adjusts to the medication.

Commonly reported side effects include:

• Dizziness or lightheadedness, particularly on standing up suddenly
• Fatigue or tiredness
• Dry cough — a well-known class effect of ACE inhibitors including Ramipril
• Slow heart rate (bradycardia)
• Headache
• Nausea or gastrointestinal discomfort

Less common but clinically significant side effects:

• Hypotension (low blood pressure), especially after the first dose
• Cold extremities (hands and feet)
• Sleep disturbances
• Elevated potassium levels (hyperkalemia)
• Worsening of renal function in susceptible patients

Patients experiencing severe dizziness, fainting, signs of angioedema (swelling of the face, lips, throat, or tongue), or difficulty breathing should seek immediate medical attention and discontinue use only under physician supervision.

Important Precautions and Contraindications

This combination is contraindicated in patients with known hypersensitivity to Metoprolol, Ramipril, any other beta-blocker, or any ACE inhibitor. It is also contraindicated in patients with severe hepatic disease, uncontrolled heart failure, unstable angina, AV block (second or third degree), severe bradycardia, or a history of angioedema related to prior ACE inhibitor use.

This medication is not recommended during pregnancy or breastfeeding. It is not indicated for use in patients under 18 years of age. Patients with diabetes should use this medication with caution as Metoprolol may mask some symptoms of hypoglycemia.

Patients should never stop taking this medication abruptly without physician guidance — sudden discontinuation of Metoprolol Succinate can lead to rebound hypertension, worsening angina, or acute cardiac events.

Drug Interactions

Metoprolol Succinate Extended Release and Ramipril Tablets may interact with the following:

• Angiotensin Receptor Blockers (ARBs) such as losartan or valsartan — risk of hypotension and hyperkalemia
• Potassium-sparing diuretics such as spironolactone — increased risk of elevated potassium levels
• NSAIDs such as ibuprofen or naproxen — may reduce the antihypertensive effect of Ramipril
• Lithium — Ramipril can increase lithium plasma levels, raising toxicity risk
• Alcohol, antihypertensives, or barbiturates — may exacerbate blood pressure-lowering effects
• Sacubitril/Valsartan — concomitant use with ACE inhibitors is contraindicated due to angioedema risk

Always inform your prescribing physician about all medications, supplements, and herbal products currently being taken before starting this combination. 

Choose Steris Healthcare For Metoprolol and Ramipril Tablets

When it comes to trusted cardiovascular combination therapy, Steris Healthcare stands as a name that healthcare professionals and patients across India rely on — and for very good reason.

Steris Healthcare manufactures Metoprolol Succinate Extended Release and Ramipril Tablets with an unwavering commitment to pharmaceutical precision, quality standards, and patient safety. Every tablet that leaves a Steris facility is the result of stringent quality control processes, GMP-certified manufacturing practices, and formulation expertise built over years of dedicated service to the cardiovascular care segment.

Pharmaceutical Grade Quality You Can Trust
Steris Healthcare's Metoprolol and Ramipril combination tablet is formulated to deliver consistent, controlled drug release across the full 24-hour dosage interval — ensuring stable blood pressure management without the peaks and troughs of inferior formulations.

Clinically Aligned Formulation
Each tablet is developed in strict alignment with established clinical guidelines for hypertension, chronic heart failure, and angina management — giving prescribing physicians complete confidence in what they recommend to their patients.

Accessible Cardiovascular Care 
Steris Healthcare believes that life-saving cardiovascular medication should be accessible, affordable, and available when patients need it most. Their Metoprolol and Ramipril tablets are distributed through a wide and dependable supply chain network across India.  

Frequently Asked Questions (FAQ):

Q1. What is Metoprolol Succinate Extended Release and Ramipril Tablet used for?

A: Metoprolol Succinate and Ramipril — combined in one tablet — are prescribed to treat high blood pressure, heart failure, and angina effectively in adults.

Q2. Can this tablet be taken long-term?

A: Yes — it is often prescribed for long-term cardiovascular management under regular physician supervision.

Q3. Does Ramipril in this tablet cause dry cough?

A: Yes — dry cough is a known ACE inhibitor side effect; consult your doctor if it persists.

Q4. Can I stop taking this tablet once my blood pressure is normal?

A: No — never stop abruptly; doing so can cause dangerous rebound high blood pressure.

Q5. Can this tablet be taken with food?

A: Yes — it can be taken with or without food, but always swallow it whole.

Q6. How long does this combination take to lower blood pressure?

A: Blood pressure begins to lower within hours, with full benefits seen over several weeks.